57.29
price down icon2.55%   -1.50
after-market アフターアワーズ: 56.45 -0.84 -1.47%
loading
前日終値:
$58.79
開ける:
$58.74
24時間の取引高:
1.27M
Relative Volume:
0.92
時価総額:
$7.58B
収益:
$947.36M
当期純損益:
$392.47M
株価収益率:
18.97
EPS:
3.02
ネットキャッシュフロー:
$392.71M
1週間 パフォーマンス:
-6.68%
1か月 パフォーマンス:
-12.08%
6か月 パフォーマンス:
+10.66%
1年 パフォーマンス:
+48.27%
1日の値動き範囲:
Value
$56.47
$58.99
1週間の範囲:
Value
$56.47
$62.14
52週間の値動き範囲:
Value
$37.97
$66.00

Halozyme Therapeutics Inc Stock (HALO) Company Profile

Name
名前
Halozyme Therapeutics Inc
Name
セクター
Healthcare (1155)
Name
電話
(858) 794-8889
Name
住所
12390 EL CAMINO REAL, SAN DIEGO, CA
Name
職員
350
Name
Twitter
@halozymeinc
Name
次回の収益日
2025-02-18
Name
最新のSEC提出書
Name
HALO's Discussions on Twitter

HALO を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
HALO
Halozyme Therapeutics Inc
57.29 7.58B 947.36M 392.47M 392.71M 3.02
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
477.52 127.47B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
561.49 62.43B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
595.70 37.03B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
232.75 31.06B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
229.22 26.16B 3.81B -644.79M -669.77M -6.24

Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-10-07 ダウングレード Wells Fargo Overweight → Equal Weight
2024-09-19 ダウングレード JP Morgan Overweight → Neutral
2024-06-07 ダウングレード Piper Sandler Overweight → Neutral
2024-02-29 開始されました TD Cowen Outperform
2023-07-24 ダウングレード Goldman Buy → Neutral
2023-07-24 開始されました H.C. Wainwright Buy
2023-05-10 アップグレード Piper Sandler Neutral → Overweight
2023-03-27 再開されました Berenberg Buy
2023-03-16 ダウングレード SVB Securities Outperform → Market Perform
2022-12-21 再開されました Morgan Stanley Overweight
2022-11-28 開始されました Wells Fargo Overweight
2022-09-09 開始されました Morgan Stanley Overweight
2022-05-23 開始されました SVB Leerink Outperform
2021-06-14 開始されました Evercore ISI Outperform
2021-05-17 開始されました SVB Leerink Outperform
2021-05-11 ダウングレード Piper Sandler Overweight → Neutral
2021-01-21 繰り返されました The Benchmark Company Buy
2020-12-17 開始されました Berenberg Buy
2020-09-14 再開されました JP Morgan Overweight
2020-07-01 開始されました The Benchmark Company Buy
2020-02-05 アップグレード Piper Sandler Neutral → Overweight
2020-01-09 アップグレード BMO Capital Markets Market Perform → Outperform
2020-01-08 開始されました Goldman Buy
2019-11-05 アップグレード Barclays Underweight → Equal Weight
2018-10-19 再開されました Piper Jaffray Neutral
2018-05-11 ダウングレード Barclays Equal Weight → Underweight
2018-01-24 開始されました Goldman Neutral
2017-10-16 繰り返されました Piper Jaffray Overweight
2017-01-06 ダウングレード Citigroup Buy → Neutral
2016-11-03 開始されました Deutsche Bank Buy
2015-12-04 開始されました Wells Fargo Outperform
2015-11-18 開始されました Citigroup Buy
2015-09-22 開始されました Barclays Overweight
2015-06-22 繰り返されました JP Morgan Overweight
2015-03-03 繰り返されました UBS Buy
2015-02-18 繰り返されました MLV & Co Buy
2015-01-08 繰り返されました MLV & Co Buy
すべてを表示

Halozyme Therapeutics Inc (HALO) 最新ニュース

pulisher
Apr 20, 2025

Halozyme Therapeutics (NASDAQ:HALO) Has A Rock Solid Balance Sheet - simplywall.st

Apr 20, 2025
pulisher
Apr 16, 2025

If EPS Growth Is Important To You, Halozyme Therapeutics (NASDAQ:HALO) Presents An Opportunity - Yahoo Finance

Apr 16, 2025
pulisher
Apr 11, 2025

Biotech Stock Bounces From Support, Shows Relative Strength Amid Volatile Market - MSN

Apr 11, 2025
pulisher
Apr 11, 2025

Halozyme Announces FDA Approval of argenx's VYVGART® Hytrulo Pre - GuruFocus

Apr 11, 2025
pulisher
Apr 11, 2025

Peering Into Halozyme Therapeutics's Recent Short Interest - Benzinga

Apr 11, 2025
pulisher
Apr 11, 2025

Argenx stock rises on FDA nod for Vyvgart Hytrulo (ARGX) - Seeking Alpha

Apr 11, 2025
pulisher
Apr 11, 2025

Halozyme Therapeutics Reports FDA Approval for Self-Injectable Syringe Developed in Partnership With Argenx - marketscreener.com

Apr 11, 2025
pulisher
Apr 10, 2025

Halozyme :FDA Oks Argenx' VYVGART Hytrulo Prefilled Syringe For Generalized Myasthenia Gravis & CIDP - Nasdaq

Apr 10, 2025
pulisher
Apr 10, 2025

Halozyme Announces FDA Approval of argenx's VYVGART® Hytrulo Prefilled Syringe Co-Formulated with ENHANZE® for Self-Injection for Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy - Citizen Tribune

Apr 10, 2025
pulisher
Apr 10, 2025

J&J, Halozyme win EU nod for injectable Rybrevant in lung cancer - MSN

Apr 10, 2025
pulisher
Apr 10, 2025

argenx Announces FDA Approval of VYVGART Hytrulo Prefilled Syringe for Self-Injection in Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy - GlobeNewswire Inc.

Apr 10, 2025
pulisher
Apr 10, 2025

Game-Changing FDA Approval: New Self-Injectable Treatment Transforms Rare Disease Care - Stock Titan

Apr 10, 2025
pulisher
Apr 09, 2025

Halozyme Therapeutics (HALO) Gains EU Approval for Injectable Co - GuruFocus

Apr 09, 2025
pulisher
Apr 09, 2025

J&J, Halozyme get EU nod for Darzalex SC to treat multiple myeloma - Seeking Alpha

Apr 09, 2025
pulisher
Apr 09, 2025

European Commission Approved Subcutaneous Darzalex (Daratumumab) Based Quadruplet Regimen - marketscreener.com

Apr 09, 2025
pulisher
Apr 09, 2025

Halozyme Reports EC Approval For Indication Extension Of DARZALEX Co-formulated With ENHANZE - Nasdaq

Apr 09, 2025
pulisher
Apr 09, 2025

European Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility - Quantisnow

Apr 09, 2025
pulisher
Apr 08, 2025

Halozyme Therapeutics : Announces Roche Receives FDA Approval For Phesgo™ (Fixed-Dose Combination Of Perjeta® And Herceptin® For Subcutaneous Injection) Utilizing 's ENHANZE® Technology For The Treatment Of Patients With HER2-Positive Bre - MarketScreener

Apr 08, 2025
pulisher
Apr 08, 2025

Halozyme Therapeutics : To Receive $10 Million Milestone Payment From Janssen - MarketScreener

Apr 08, 2025
pulisher
Apr 07, 2025

Halozyme (HALO) Secures European Approval for J&J Antitumor Inje - GuruFocus

Apr 07, 2025
pulisher
Apr 07, 2025

EC approves new lung cancer treatment using Halozyme technology By Investing.com - Investing.com South Africa

Apr 07, 2025
pulisher
Apr 07, 2025

European Commission Approves Subcutaneous RYBREVANT® (amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer - The Malaysian Reserve

Apr 07, 2025
pulisher
Apr 07, 2025

Halozyme Says EC Approved Subcutaneous Rybrevant For Advanced EGFR-Mutated NSCLC - Nasdaq

Apr 07, 2025
pulisher
Apr 07, 2025

EC approves new lung cancer treatment using Halozyme technology - Investing.com

Apr 07, 2025
pulisher
Apr 07, 2025

European Commission Approves Subcutaneous Rybrevant® (Amivantamab) - MarketScreener

Apr 07, 2025
pulisher
Apr 03, 2025

KLP Kapitalforvaltning AS Makes New Investment in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat

Apr 03, 2025
pulisher
Apr 01, 2025

Halozyme Therapeutics director Jeffrey Henderson sells $32,217 in stock - Investing.com Australia

Apr 01, 2025
pulisher
Apr 01, 2025

Halozyme Therapeutics director Jeffrey Henderson sells $32,217 in stock By Investing.com - Investing.com South Africa

Apr 01, 2025
pulisher
Apr 01, 2025

4,812 Shares in Halozyme Therapeutics, Inc. (NASDAQ:HALO) Purchased by EntryPoint Capital LLC - MarketBeat

Apr 01, 2025
pulisher
Mar 31, 2025

Corebridge Financial Inc. Has $9.81 Million Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat

Mar 31, 2025
pulisher
Mar 31, 2025

Long Term Trading Analysis for (HALO) - news.stocktradersdaily.com

Mar 31, 2025
pulisher
Mar 31, 2025

Halozyme: Bristol Myers Squibb Secures CHMP's Positive Opinion For New Cancer Drug Delivery Method - Nasdaq

Mar 31, 2025
pulisher
Mar 31, 2025

Halozyme Announces Bristol Myers Squibb Received Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) with ENHANZE® Across Multiple Solid Tumor Indications - Quantisnow

Mar 31, 2025
pulisher
Mar 31, 2025

Major Breakthrough: New Cancer Drug Delivery Method Gets EU Panel Support - Stock Titan

Mar 31, 2025
pulisher
Mar 28, 2025

Why Is Acadia (ACAD) Down 11.1% Since Last Earnings Report? - Yahoo Finance

Mar 28, 2025
pulisher
Mar 27, 2025

Merck plans to launch US subcutaneous version of Keytruda on October 1 - Reuters

Mar 27, 2025
pulisher
Mar 27, 2025

Halozyme Therapeutics (HALO) Stock Price, News & Analysis - MarketBeat

Mar 27, 2025
pulisher
Mar 26, 2025

Myriad (MYGN) Down 17.1% Since Last Earnings Report: Can It Rebound? - Yahoo Finance

Mar 26, 2025
pulisher
Mar 24, 2025

Halozyme stock soars to all-time high of $65.54 By Investing.com - Investing.com South Africa

Mar 24, 2025
pulisher
Mar 24, 2025

Halozyme stock soars to all-time high of $65.54 - Investing.com India

Mar 24, 2025
pulisher
Mar 24, 2025

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick - Yahoo Finance

Mar 24, 2025
pulisher
Mar 21, 2025

Halozyme Announces Retirement of Chief Technical Officer - TipRanks

Mar 21, 2025
pulisher
Mar 21, 2025

Halozyme announces CTO retirement, effective immediately - Investing.com India

Mar 21, 2025
pulisher
Mar 21, 2025

Halozyme announces CTO retirement, effective immediately By Investing.com - Investing.com Australia

Mar 21, 2025
pulisher
Mar 21, 2025

Drug developers show mixed performance in early 2025 - BioWorld MedTech

Mar 21, 2025
pulisher
Mar 21, 2025

Halozyme Therapeutics (HALO) is a Top-Ranked Value Stock: Should You Buy? - Yahoo Finance

Mar 21, 2025
pulisher
Mar 21, 2025

Halozyme Joins the $1 Billion Club - Yahoo Finance

Mar 21, 2025
pulisher
Mar 17, 2025

AstraZeneca signs $1.35B Alteogen deal for subcutaneous cancer drugs - Fierce Pharma

Mar 17, 2025
pulisher
Mar 14, 2025

Halozyme Therapeutics: Steady Growth In A Challenged Market (NASDAQ:HALO) - Seeking Alpha

Mar 14, 2025

Halozyme Therapeutics Inc (HALO) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$20.07
price up icon 0.15%
$69.51
price down icon 4.32%
$32.19
price down icon 1.26%
$25.22
price up icon 2.48%
$101.81
price up icon 3.09%
biotechnology ONC
$229.22
price down icon 0.76%
大文字化:     |  ボリューム (24 時間):